Jensen Investment Management Inc. Purchases Shares of 206,612 Eli Lilly and Company $LLY

Jensen Investment Management Inc. acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 206,612 shares of the company’s stock, valued at approximately $161,060,000. Eli Lilly and Company accounts for approximately 1.9% of Jensen Investment Management Inc.’s portfolio, making the stock its 22nd biggest position.

Other hedge funds have also modified their holdings of the company. Intech Investment Management LLC grew its stake in Eli Lilly and Company by 18.9% during the 2nd quarter. Intech Investment Management LLC now owns 168,692 shares of the company’s stock worth $131,500,000 after purchasing an additional 26,857 shares in the last quarter. Sculati Wealth Management LLC grew its position in shares of Eli Lilly and Company by 16.4% during the second quarter. Sculati Wealth Management LLC now owns 2,131 shares of the company’s stock worth $1,661,000 after buying an additional 300 shares in the last quarter. Cetera Investment Advisers increased its stake in shares of Eli Lilly and Company by 3.1% during the second quarter. Cetera Investment Advisers now owns 253,839 shares of the company’s stock worth $197,876,000 after buying an additional 7,552 shares during the period. Creative Planning raised its holdings in Eli Lilly and Company by 3.5% in the second quarter. Creative Planning now owns 266,992 shares of the company’s stock valued at $208,128,000 after acquiring an additional 9,016 shares in the last quarter. Finally, Advisory Resource Group lifted its stake in Eli Lilly and Company by 4.2% in the second quarter. Advisory Resource Group now owns 2,014 shares of the company’s stock worth $1,570,000 after acquiring an additional 82 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 0.2%

NYSE:LLY opened at $1,024.67 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,033.62. The stock’s 50 day moving average price is $826.89 and its 200 day moving average price is $780.14. The company has a market capitalization of $968.70 billion, a PE ratio of 66.97, a P/E/G ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Analysts Set New Price Targets

A number of brokerages have commented on LLY. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Guggenheim reaffirmed a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 16th. Leerink Partners upgraded Eli Lilly and Company from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $886.00 to $1,104.00 in a report on Monday, November 10th. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Finally, Cantor Fitzgerald increased their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,015.11.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.